UPDATE: Brean Capital Downgrades Pernix Therapeutics (PTX) to Hold
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
(Updated - August 12, 2016 10:35 AM EDT)
Brean Capital downgraded Pernix Therapeutics (NASDAQ: PTX) from Buy to Hold and removed its price target. The change followed the release of Q2 results. Analyst Difei Yang said the pathway to sustainable revenue growth and profitability is unclear.
"Pernix missed on revenue yesterday, $36.8 mil vs. Street’s $40.3 mil, but approximately met consensus estimates on GAAP EPS of ($0.47). We are disappointed about the halting of progress on the sNDA of Treximet and believe the extended life would have benefited the company. Pernix sold $12.4 million during Q2, and it is possible an additional dilutive capital raise lies ahead. We will move to the sidelines and downgrade our rating to Hold from Buy," said Yang.
Shares of Pernix Therapeutics closed at $0.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Seaport Global Securities Upgrades Flowserve Corp. (FLS) to Buy
- Teradyne (TER) PT Raised to $28 at Deutsche Bank; Reiterates Buy
- Procter & Gamble (PG) PT Raised to $96 at UBS Following 2Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades
Related EntitiesBrean Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!